Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry study - The Lancet Regional Health –
Treatment Options for Non-Small Cell Lung Cancer Harboring Uncommon *EGFR* Mutations | Published in healthbook TIMES Oncology Hematology
Frontiers | Various Subtypes of EGFR Mutations in Patients With NSCLC Define Genetic, Immunologic Diversity and Possess Different Prognostic Biomarkers
Effect of gene mutations on the prognosis of lung adenocarcinomas. Blue... | Download Scientific Diagram
Differences among lesions with exon 19, exon 21 EGFR mutations and wild types in surgically resected non-small cell lung cancer | Scientific Reports
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer—is there a “tail plateau” in the survival curve of these patients? | BMC Cancer | Full Text
The benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study | Scientific Reports
Kaplan–Meier estimates of overall survival according to EGFR status... | Download Scientific Diagram
The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer | Scientific Reports
Cytoplasmic ERβ1 expression is associated with survival of patients with Stage IV lung adenocarcinoma and an EGFR mutation at exon 21 L858R subsequent to treatment with EGFR‑TKIs
A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes | SpringerLink
An exon 21 L858R EGFR mutation is associated with a decreased survival... | Download Scientific Diagram
Critical Review of *EGFR*-Mutated NSCLC What We Do and Do Not Know | Published in healthbook TIMES Oncology Hematology
Association between EGFR exon 19 or exon 21 mutations and survival rates after first‑line EGFR‑TKI treatment in patients with non‑small cell lung cancer
Kaplan-Meier curves for overall survival of lung adenocarcinoma... | Download Scientific Diagram
Survival‑associated factors of first‑line EGFR‑tyrosine kinase inhibitor responders and non‑responders in lung adenocarcinoma patients with common EGFR mutations
Kaplan-Meier survival analysis of patients with NSCLC with or without... | Download Scientific Diagram
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC | NEJM
The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis | Scientific Reports
THE LIVES AFFECTED BY EGFR EXON 20 INSERTION MUTATIONS
Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program - ScienceDirect
